Want to see ALLR full AI Analyst Report?
ALLR Stock Chart & Stats
$1.14
-$0.01(-0.99%)
At close: 4:00 PM EST
$1.14
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$0.77 - $2.35
Previous CloseN/A
Volume542.33K
Average Volume (3M)146.33K
Market Cap
$18.54M
Enterprise Value$23.00M
Total Cash (Recent Filing)$19.81M
Total Debt (Recent Filing)$21.50M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Oct 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,910,724
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue66.68
Enterprise Value/Gross Profit62.01
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$10.25Price Target Upside799.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened IP For Stenoparib DiagnosticA long-term U.S. patent to 2042 for the stenoparib DRP® companion diagnostic materially raises barriers to entry for competitors and strengthens negotiating leverage with partners and regulators, supporting durable commercial exclusivity and potential premium pricing on companion-test enabled indications.
Proprietary DRP® Predictive PlatformOwning a validated predictive biomarker platform improves trial efficiency and can raise responder rates, lowering development risk and accelerating regulatory/partner interest. This structural asset enhances long-term partnering and licensing prospects across oncology programs.
Low Financial LeverageZero debt and positive equity provide balance-sheet flexibility, lowering immediate default or covenant risk and allowing the company to pursue clinical programs or strategic deals without interest burdens; this durable liquidity posture aids runway management.
Bears Say
High Cash BurnSustained negative operating and free cash flows at this magnitude versus minimal revenue indicate persistent burn. Without a material inflection from partnerships, approvals, or financing, the company faces structural cash runway pressure that forces strategic trade-offs or dilutive capital raises.
Very Limited Revenue And ProfitabilityWith revenue measured in the hundreds of thousands and multi-million operating losses, the business model lacks demonstrated commercial revenue generation. This leaves the company dependent on clinical progress to create durable revenue, making near-term scalability and sustainability uncertain.
Reliance On External Financing/dilution RiskBoard-authorized equity issuance and a larger incentive pool signal anticipated fundraising and potential dilution. Reliance on equity financings is a structural constraint for shareholders and reflects an ongoing need to replenish capital to fund R&D and trials absent commercial cash flow.
Allarity Therapeutics News
ALLR FAQ
What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $0.77 and its highest was $2.35 in the past 12 months.
What is Allarity Therapeutics, Inc.’s market cap?
Allarity Therapeutics, Inc.’s market cap is $18.54M.
When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
Allarity Therapeutics, Inc.’s upcoming earnings report date is Oct 13, 2026 which is in 92 days.
How were Allarity Therapeutics, Inc.’s earnings last quarter?
Allarity Therapeutics, Inc. released its earnings results on May 15, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Allarity Therapeutics, Inc. overvalued?
According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Undervalued.
Does Allarity Therapeutics, Inc. pay dividends?
Allarity Therapeutics, Inc. does not currently pay dividends.
What is Allarity Therapeutics, Inc.’s EPS estimate?
Allarity Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allarity Therapeutics, Inc. have?
Allarity Therapeutics, Inc. has 15,910,724 shares outstanding.
What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
Allarity Therapeutics, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.926%.
Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
ALLR Stock 12 Month Forecast
Average Price Target
$10.25
▲(799.12% Upside)
Technical Analysis
Ownership Overview
7.69% Insiders
1.90% Mutual Funds
1.49% Other Institutional Investors
87.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---